Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Infection biology training network: shaping the future of infectious diseases treatments (INBIONET)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Initial Training Networks
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: United Kingdom,Ireland,United Kingdom,Germany,Switzerland,Austria,France,France,Spain
Call:  (FP7-PEOPLE-2012-ITN, 2012)
Start date: 2013-01-01
End date: 2016-12-31
Duration (months): 48.0
Total project cost (EUR): 3968982.54
EU funding (EUR): 3968982.54
Participants: 10
Project status: CLOSED

The increasing number of bacteria resistant to all antibiotics and antimicrobials and the virtual lack of antiviral drugs make necessary to develop therapeutics based on new targets/approaches. European-wide-acting sectors must permanently improve their capabilities and capacities to cope with these challenges. Thus, the demand for experts trained to understand infectious diseases in their whole complexity is rising. INBIONET is an initiative from seven academic groups internationally recognized in the fields of microbial pathogenesis, innate immunity and molecular recognition, an intensive research SME, Preclin Biosystems, a multinational pharmaceutical company, Sanofi-Aventis, and a technological park (ParcBit). INBIONET partners will embark on the analysis of bacteria, viruses and enteric parasites specified by various infection strategies to identify cellular pathways important for infection as well as pathogen determinants involved in disease progression. Therefore, trainees will receive a comprehensive overview of some key concepts that pathogens use to ensure their success. It is expected that this knowledge will lead to the development of innovative therapies based on the modulation of the host-pathogen interface. INBIONET training will also focus on key aspects dealing with know-how transfer between academia and industries, and entrepreneurship. The four-year INBIONET training programme, at the interface between microbiology, immunology and cellular biology, should help to train the next generation of European scientists in the competitive field of “microbial anti-immunology” and set the grounds for new preventatives and therapeutics. INBIONET academic and industrial partners do provide the necessary critical mass to offer a top level training not currently offered in such dimension by any European academic institution thereby giving trainees a thorough and truly interdisciplinary background to meet the demands of the European (scientific) labour market.

Keywords: infection biology,innate immunity,host-pathogen interactions,bacteria,viruses,parasites,nf-kb,interferon,pattern recognition receptors
Innovative Modelling for Pharmacological Advances through Collaborative Training (IMPACT)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Initial Training Networks
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: United Kingdom,Sweden
Call:  (FP7-PEOPLE-2012-ITN, 2012)
Start date: 2013-01-01
End date: 2016-12-31
Duration (months): 48.0
Total project cost (EUR): 1467958.8
EU funding (EUR): 1467958.8
Participants: 2
Project status: CLOSED

This project forms an interdisciplinary collaborative partnership between AstraZeneca (AZ, Sweden) and the University of Warwick (UoW, UK) to train Early Stage Researchers (ESRs) in systems modelling tools and techniques enabling them to perform research projects at the forefront of international pharmacokinetic (PK) and pharmacodynamic (PD) analysis. This project will build upon extremely strong research and training links already formed between the UoW and AZ (UK) in PK/PD modelling and will support the clearly identified need within AZ worldwide to train more personnel with high-level skills in systems modelling for future drug development. The most effective drugs are those that produce clinical benefit by modulating disease biology and are given to patients at an optimal dose and schedule. In order to deliver new drugs it is necessary to quantify, translate and simulate from the test tube to the patient. This includes being able to model biological pathways, quantify relationships between dose/exposure, target engagement, efficacy and safety in pre-clinical tests and humans and utilising all relevant information efficiently and quantitatively. The development and application of innovative modelling techniques to tackle current problems in drug development allied to the training of researchers with skills to perform these tasks are key drivers for the partners. A unique blend of multidisciplinary training will be offered to the ESRs by both partners through well-established, extensive and innovative programmes at their sites with the appointed ESRs registered for PhDs at the UoW. The ESR projects will be based on research problems and data generated at AZ. The outcomes of the projects will not only maintain the positions of AZ and the UoW at the forefront of international research in PK/PD analysis, but also greatly enhance the EU’s standing worldwide in this area, whilst also enhancing the future job prospects of those trained within the AZ group worldwide

Keywords: pharmacology,mathematical modelling,pharmacokinetics,pharmacodynamics,drug development,quantitative and systems pharmacology,systems modelling,multidisciplinary,safe and efficacious drugs
Towards 0.7 Terahertz Silicon Germanium Heterojunction Bipolar Technology (DOTSEVEN)

Framework: FP7 — Cooperation
Programme: Information and Communication Technologies
Destination: Alternative Paths to Components and Systems
Action type: Collaborative project
Countries involved: Germany,Germany,Italy,Germany,Germany,France,Germany,Austria,Sweden,Netherlands,France,Sweden
Call:  (FP7-ICT-2011-8, 2011)
Start date: 2012-10-01
End date: 2016-06-30
Duration (months): 45.0
Total project cost (EUR): 12281856.0
EU funding (EUR): 8600000.0
Participants: 15
Project status: CLOSED

DOTSEVEN is a 3.5 year IP proposal for a very ambitious R&D project targeting the development of Silicon Germanium (SiGe) Heterojunction Bipolar Transistor (HBT) technologies with cut-off frequencies (fmax) of around 700 GHz. Special attention will be paid to clearly demonstrate the capabilities and benefits of this technology with benchmark circuits and advanced system applications in the 0.1 to 1 THz range like THz imaging and sensing, wireless Gb/s communications and millimeter-wave radar. For a given lithography node, HBTs provide much higher cut-off frequencies compared to CMOS transistors while offering higher power density and better analog performance. SiGe HBT technology and SiGe HBT enhanced CMOS (SiGe BiCMOS) are key enablers for demanding mm-wave systems requiring more than a few µWatts of RF output power (which limits the applicability of even very advanced CMOS) and also offer high integration levels at low cost which precludes expensive and less integrated III-V solutions. 10 out of the 12 DOTSEVEN participants were already partnering in the predecessor FP7 project DOTFIVE which succeeded for the first time to push fmax of SiGe HBTs (at room temperature) into the 500 GHz region thus setting a new world-wide benchmark. Triggered by the impressive DOTFIVE results, several activities in the rest of the world already have started to catch up or even surpass our achievements. The main objective of the highly qualified and motivated DOTSEVEN consortium is therefore to significantly expand the successful work of DOTFIVE, to further strengthen Europe's leading edge position in SiGe HBT technology and modeling as well as SiGe enabled mm-wave applications and to stay significantly ahead of non-European competition. A powerful and success-proven consortium has been set-up to achieve these goals. It consists of 5 industrial partners (including 3 SMEs) and 9 well distinguished academic research institutes spread all over Europe.

Keywords: silicon germanium,terahertz,thz imaging,gb/s communication,autoradar,mmwave sensing,hbt
Medicinal Chemistry Open Innovation Doctorates (OPENMEDCHEM)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Initial Training Networks
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Belgium,Spain
Call:  (FP7-PEOPLE-2012-ITN, 2012)
Start date: 2012-10-01
End date: 2016-09-30
Duration (months): 48.0
Total project cost (EUR): 690110.64
EU funding (EUR): 690110.64
Participants: 2
Project status: CLOSED

The establishment of influential public and private public partnerships fostering true collaboration between big Pharma and universities for a non-profit end goal has opened the door for stronger interaction and integration. This structural change has come to stay and is slowly permeating other sectors in which the commercial return on investment is clear (Drug. Discov. Today, 2009, 14, 1003). This new paradigm is also creating opportunities for young scientists to experience and understand both industrial and academic points of view when it comes to the early discovery and pharmaceutical development of new drugs. A new generation of scientists trained under a public-private partnership will find itself in a privileged position in terms of employment opportunities. Moreover, the close ties arising from this interaction will improve the dialogue between Pharma and academia, resulting in faster implementation of relevant medicinal chemistry basic science discoveries into the Pharma pipeline and a better understanding within academia of the critical limiting factors behind falling productivity in the Pharma sector. In this context, neglected diseases research and development is opening important new avenues of collaboration between academia and industry. The scientific focus of this EID project will be on the design and synthesis of novel antituberculosis drugs. The fellows will have unique access to corporate HTS screening hits while being exposed to both industrial and academic med chem strategies and philosophies. These chemical efforts will be supported by the application of state of the art chemical biology tools for investigation of compound activity profiles. In particular, the new single cell microfluidic-microscopy system at the industrial partner´s site will allow for in depth study of the activities of the new compounds, while also providing a platform for investigating the gross modes of action of both novel and known antituberculars.

Keywords: industrial doctorates,drug discovery,tuberculosis,medicinal chemistry,microfluidics,organic synthesis
Integration and international migration: pathways and integration policies (INTEGRIM)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Initial Training Networks
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Spain,Belgium,United Kingdom,Portugal,Netherlands,Türkiye,Hungary,France
Call:  (FP7-PEOPLE-2012-ITN, 2012)
Start date: 2013-01-01
End date: 2017-04-30
Duration (months): 52.0
Total project cost (EUR): 3492803.6
EU funding (EUR): 3492803.6
Participants: 8
Project status: CLOSED

According to UN assessments, there are 214 million international migrants worldwide and another 740 million internal migrants . The OECD highlights that there seems little likelihood of substantial reductions in numbers of international migrants in the current decade . Rises in global population, new demographic trends including ageing population, environmental deterioration and an increased globalisation of the economy are some of the factors which will encourage emigration flows in coming years. International migration, firmly at the top of the EU’s political agenda, must be analysed from the integration perspective as the key factor for the future cohesion of European societies. The INTEGRIM programme is developed by a sound and well established network of 8 full partner academic institutions and 6 non-academic associated partners from the private and public sector, civil society and international organisations with outstanding research and training credentials on migration and integration issues. The aim of this programme is to structure the existing high-quality research capacity on migration and integration policies and processes in Europe through 480 person-months of Early-Stage Researchers. INTEGRIM will consider processes and policies concerning integration of foreign nationals within EU countries, including third-country nationals and European nationals migrating to other European states when they face substantial integration difficulties. The existing fruitful collaboration among the Network’s partners through existing research networks such as the EC acknowledged network of excellence IMISCOE has evidenced the capacity and added value to pool the talent to the benefit of a common critical mass and enhancement of the academic knowledge. INTEGRIM aims to enhance academic research capacity, encourage policy-relevant research on integration and diversity management and facilitate the use of that research by governments and non-governmental organisations.

Keywords: s106 globalization - migration - interethnic relations
TRAINING NETWORK ON ORGANIC OPTOELECTRONICS INTEGRATED WITH LIVING SYSTEMS FOR NEUROSCIENCE INVESTIGATIONS AND APPLICATIONS (OLIMPIA)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Initial Training Networks
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Italy,Norway,France,Italy,Spain,Germany,United Kingdom
Call:  (FP7-PEOPLE-2012-ITN, 2012)
Start date: 2012-10-01
End date: 2016-09-30
Duration (months): 48.0
Total project cost (EUR): 4011185.41
EU funding (EUR): 4011185.41
Participants: 9
Project status: CLOSED

OLIMPIA is a training network initiative built on research and development of innovative organic optoelectronic devices interfaced and integrated with living systems. The living systems of choice are neural cells (glia and neuron) that will be interfaced and integrated in vitro and in vivo with different organic electronic and optoelectronic devices (such as OLED, OFET/OLET, OECT, OPD). The major objective of OLIMPIA is to establish an innovative training program aimed at enabling and supporting the development of a novel supradisciplinary field that combines the worlds of organic optoelectronics and of neuroscience. Novel tools based on organic optoelectronic devices will be engineered and developed to stimulate and to record neuron bioelectrical activity, such as neuron excitability and membrane polarization, as well as to modulate cell proliferation and neurite outgrowth. The OLIMPIA research will provide radically new understanding of neural cell-cell communication processes and will impact a wide variety of fields, from biomedical research to neuro-regenerative medicine. The OLIMPIA consortium is both interdisciplinary and intersectorial. It includes key European players with long standing and internationally recognized research tradition in the field of organic electronics and optoelectronics, organic synthesis as well as neural cell biology and neurophysiology and, as such, is uniquely qualified to implement this ambitious supradisciplinary training program. Moreover, the consortium combines 10 partners belonging to 6 European countries from academia, public research centers and industrial labs thereby offering an exciting and broad training landscape to the new generation of researchers.

Keywords: organic optoelectronics neuroscience in-vitro and in-vivo organic materials/neural systems functional interfaces stimulation and readout of bioelectrical activity neuroorganic optoelectronics
Advanced Technologies for Biogas Efficiency Sustainability and Transport (ATBEST)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Initial Training Networks
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: United Kingdom,Germany,Germany,Ireland,Ireland,Sweden,Sweden
Call:  (FP7-PEOPLE-2012-ITN, 2012)
Start date: 2013-07-01
End date: 2017-06-30
Duration (months): 48.0
Total project cost (EUR): 3864393.72
EU funding (EUR): 3864393.72
Participants: 9
Project status: CLOSED

The ATBEST ITN will develop innovative research and training for the biogas industry in Europe. It comprises eight training sites located in the UK, Ireland, Germany and Sweden and is a multidisciplinary collaboration between internationally-renowned research teams and industrial partners, each with complementary expertise in a wide range of environmental technologies. 12 ESRs and 2 ERs will be recruited and each will participate in secondments, industrially relevant training and 3 Summer Schools. The aim is to establish long-term collaborations and develop structured research and training relevant to industry and academia along the biogas supply chain (biogas production from feedstock to its utilisation as energy). The project will reinforce and expand existing research links to standardise and advance biogas training. The Renewable Energy Directive (2009/28/EC) sets EU targets of a 20% share of energy from renewable sources in the overall energy mix by 2020. However, current technologies are not sufficient to reach these targets in a sustainable manner. ATBEST will develop new and innovative technologies for the biogas sector, to enable Europe to implement its Energy 2020 strategy and to address the challenges of increasing energy demand and energy generation costs. The young researchers will create new knowledge for the biogas industry, and will develop advanced technical and commercial skills to enhance their employment opportunities upon completion of the programme. ATBEST outputs will be disseminated across Europe – to policy makers, applicable sectors (including energy, agri-food and transport), academia and to the general public. An Innovation, Exploitation and Employability Steering Group will input industrial and policy expertise from the Associate Partners to the training programme. The Associate Partners will also provide feedback to each fellow and provide additional industrial secondment opportunities.

Keywords: environment & sustainability,chemical engineering,anaerobic digestion,microbial processes,biogas upgrading,biogas utilisation.
Vaccine Design and Immune Responses (VADER)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Initial Training Networks
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: United Kingdom,Italy
Call:  (FP7-PEOPLE-2012-ITN, 2012)
Start date: 2012-10-01
End date: 2016-09-30
Duration (months): 48.0
Total project cost (EUR): 1174366.0
EU funding (EUR): 1174366.0
Participants: 2
Project status: CLOSED

The successful development of new vaccines depends on the interaction of industrial expertise for vaccine design and engineering with academic understanding of the mechanisms of protection afforded by the immune responses they elicit. Close interaction between both sectors expedites vaccine development and, in the context of global health, this can translate to the saving of thousands of lives. The VADER (Vaccine Design and Immune Responses) EID programme, established between the Novartis Vaccines Institute for Global Health (NVGH) in Italy and University of Birmingham (UoB) in the UK, will train four talented clinical and non-clinical fellows at the interface between academia and industry. NVGH is a company with a mission to develop affordable and effective vaccines against infectious diseases of impoverished communities in the developing world. Its first vaccine, against Salmonella Typhi, is in clinical trails in South-East Asia, with vaccines against Salmonella Paratyphi, nontyphoidal Salmonella, meningococcus and Shigella in preclinical development. UoB is an international leader in investigating immune responses to bacteria, particularly Salmonellae, and in relating immunity to microbial antigens. The two institutions have forged strong links over the last year which form the framework of the VADER programme. The fellows will work on four related projects embedded within existing vaccine programmes at NVGH where they will work as part of a team of scientists. With vaccines in clinical trials, trainees will be able to explore immune responses in human vaccinees as well as animals. In their projects, they will be trained in vaccine design and immunology and learn how differences in vaccine engineering affect immune responses. By working on both industrial and academic sides of vaccine development they receive a research training in translational and transferable skills and learn how both sectors can synergise in vaccine development.

Keywords: l602 adaptive immunity,l605 immunological memory and tolerance,l607 microbiology,l609 bacteriology,l611 prevention and treatment of infection by pathogens,vaccine design,global health
Oxford Innovative Organic Synthesis in Cancer Research Doctoral Programme (OXIOSCR)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Initial Training Networks
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: United Kingdom
Call:  (FP7-PEOPLE-2012-ITN, 2012)
Start date: 2013-03-01
End date: 2017-05-31
Duration (months): 51.0
Total project cost (EUR): 3816692.22
EU funding (EUR): 3816692.22
Participants: 1
Project status: CLOSED

The Oxford Innovative Organic Synthesis for Cancer Research IDP (OxIOSCR) will seed a revolution in the practice of organic synthesis, by training graduate synthetic chemists for the first time to integrate seamlessly chemical, biocatalytic, and reagentless organic synthesis techniques with the latest advances in reaction technology. The synthetic chemistry will be shaped by a focus on target compounds with mechanism-based substantial anti-cancer activity. This will provide a strong interdisciplinary component to the training programme, by linking with Oxford’s extensive and world-class expertise in fundamental cancer biology and medicinal chemistry. The training programme will lead automatically to more sustainable synthetic routes, new strategies for organic synthesis, a more strongly connected network of chemists and cancer biologists, and will release a generation of fully trained synthesis innovators into the academic and chemical industrial workplace. OxIOSCR is strongly intersectoral, with close involvement of 7 Associated Partners distributed over 6 European countries, crossing academic/industrial, physical/medical science, and public/private sectors.

Keywords: organic synthesis,biocatalysis,electrochemistry,flow chemistry,cancer medicinal chemistry